Table 6.
Time to progressive disease.
| Variable | All (N = 89) | Treatment naïve |
Relapsed or ≥second line |
||
|---|---|---|---|---|---|
| Bendamustine monotherapy (n = 10) | Bendamustine + rituximab combination therapy (n = 6) | Bendamustine monotherapy (n = 19) | Bendamustine + rituximab combination therapy (n = 54) | ||
| Time to progressive disease, months | |||||
| Median (95% CI) | 19.1 (14.9–21.3) | 26 (20.3–NA) | – | 21.6 (19.1–24.3) | 14.5 (12.9–18.8) |
| Mean (SE)* | 19 (1.23) | 20.3 (3.5) | – | 22.8 (2.0) | 14.8 (1.1) |
| Patients with event, n | 57 | 4 | 0 | 16 | 37 |
| Patients censored, n | 32 | 6 | 6 | 3 | 17 |
| Median length of follow up, months | 17.8 | 17.7 | 15.1 | 24.5 | 16.8 |
CI, confidence interval; NA, not available; SE, standard error.
*
Mean and SE were provided because median time to next treatment was not reached for some strata. Mean and SE may be underestimated because the largest observation was censored, and the estimation was restricted to the largest event.